Goldman Turns Bullish On Saia, Sees Room For Shipping Efficiency, Profit Growth Goldman Sachs upgraded Saia, Inc. and raised the price forecast to $410, citing potential growth opportunities and improved margins.
Alphabet Set To Gain From Google AI Innovation, 'Underappreciated' YouTube: Goldman Sachs Goldman Sachs analyst believes Alphabet Inc is well-positioned for AI era, with potential growth in Search & Other segment and YouTube revenues.
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral.
Oil Prices Rise After OPEC+ July Output Boost Viewed As Less Than Feared On Saturday, the Organization of the Petroleum Exporting Countries and its allies, including Russia, pledged to raise production by 411,000 barrels per day in July.
Google Isn’t Backing Down: Alphabet Says Antitrust Court Got It Wrong Over Search Monopoly, Vows To Fight Verdict District of Columbia Judge Amit Mehta heard the closing arguments on the case on Friday, with the final ruling expected by August.
US Regulators Reportedly Set To Ease Bank Leverage Rules In Major Post-2008 Crisis Rollback The regulation known as the Supplementary Leverage Ratio garnered further attention following a selloff of U.S. debt in April following Trump’s “Liberation Day” tariffs.
Should You Forget Amazon? Why These Unstoppable Stocks Are Better Buys As Wayne Gretzky put it, "Skate to where the puck is going, not where it has been."
Goldman Sachs President John Waldron Says Big Macro Risk Not So Much Trump Tariffs But Washington's Burgeoning Appetite For Debt Goldman Sachs President John Waldron warns bond traders see US debt as a bigger threat than trade fights, as borrowing raises long-term rates.
Beta Bionics Stock Gains After Mixed Analyst Coverage; Wolfe Bullish, Goldman Neutral Wolfe Research initiated coverage with an ‘Outperform’ rating and a $20 target, while Goldman Sachs started at ‘Neutral’ with a $16 target, citing balanced growth prospects and valuation.
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip The patient’s elevated levels of liver enzymes appear to be resolving without hospitalization or medical intervention, the company said.
Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Insiders bought these high-yielding dividend stocks in May, highlighting the potential for triple-digit total returns for income investors.
Tariffs Blocked By Court, But Goldman Sachs Says Trump Could Reimpose Them 'Within Days' US Court of International Trade blocked Trump's tariffs, but Goldman Sachs economist says White House has options to bring them back quickly.
Birkenstock Authorizes $200M Buyback, But Retail Remains Cold One of the company's investors is selling over $800 million worth of shares in a secondary market offering.
Booz Allen Hamilton Downgraded: Analyst Flags Flat Revenue Growth, Margin Pressure Goldman Sachs downgrades Booz Allen to Sell, citing flat revenue outlook, federal budget pressure, and rising margin risks from new contracts.
KRE Falls Behind XLF, Sparks SVB Collapse Flashbacks: Are ETFs Sensing Bank Trouble? KRE has declined more than 3% this year, while XLF is up more than 5%. The divergence between the two ETFs is getting larger.
Why Whirlpool's Margins Have Tailwinds Despite Memorial Day Promotions Whirlpool offered lowest Memorial Day discounts, Goldman Sachs says. Analyst maintains Buy rating, $100 target. Prices raised due to tariffs, but offset by promos.
